Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive XXXX .

@entity1 @entity632 @entity137 @entity706 @entity5 @entity229 @entity786 @entity39561 @entity1891
STUDY OBJECTIVE: To determine the efficacy and @entity137 of brief chemotherapy and involved field radiation therapy for treatment of limited-stage, histologically aggressive @entity706 . DESIGN: Single-arm prospective trial. SETTING: Comprehensive @entity5 treatment center serving the entire population of British Columbia. @entity1 : Consecutive enrollment of 78 @entity1 ranging in age from 21 to 82 years (median, 64) with limited-stage (no B symptoms, Ann Arbor stage I or II, @entity5 less than 10 cm in diameter), diffuse large cell, mixed or immunoblastic histologic characteristics of @entity706 seen at our institution between May 1980 and December 1984. All eligible @entity1 were evaluated for response and relapse-free and overall survival. INTERVENTIONS: Chemotherapy with @entity39561 ( @entity786 , @entity632 , @entity1891 , and @entity229 ) for three cycles followed by involved field radiation therapy to the original site of disease in a dose equivalent to 3000 cGy in ten fractions. MAIN RESULTS: The complete response rate was 99% (77 of 78 @entity1 ). With a median follow-up off treatment of 30 months the actuarial relapse-free survival is 84% and the overall survival is 85%. No deaths due to @entity137 occurred. CONCLUSIONS: Brief chemotherapy and involved field radiation therapy is highly successful treatment for @entity1 with limited-stage, histologically aggressive @entity706 . @entity137 of this approach is acceptable, even in the elderly. Staging laparotomy is not needed to select these @entity1 . Future trials should incorporate more effective chemotherapy programs.
